Results 201 to 210 of about 541,695 (230)
Pharmacogenomics in Acute Myeloid Leukemia [PDF]
Pharmacogenomics, 2009 Acute myeloid leukemia (AML) in adults is a heterogeneous malignant pathology with a globally unfavorable prognosis. The classification of AML allows identification of subgroups with favorable prognosis. However, besides these specific subgroups, most patients will have an intermediate or unfavorable prognosis often resulting in induction failure ...
Christophe Roumier, Meyling Cheok
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pediatric acute myeloid leukemia
Expert Review of Anticancer Therapy, 2012Pediatric acute myeloid leukemia (AML) is currently associated with survival rates as high as 70%. However, many events still occur, side effects are significant, and late effects occur and can even be life-threatening. Thus, the treatment of pediatric AML still needs further improvement.
openaire +4 more sources
Immunotherapy for acute myeloid leukemia [PDF]
Current Oncology Reports, 2005 Immunotherapeutic strategies have become part of standard cancer treatment. Chimeric and humanized antibodies have demonstrated activity against a variety of tumors. Although the humanized anti-CD33 antibody HuM195 has only modest activity against overt acute myeloid leukemia (AML), it can eliminate minimal residual disease in acute promyelocytic ...
openaire +2 more sources
Tipifarnib in acute myeloid leukemia
Drugs of Today, 2007Treatment of older patients with acute myeloid leukemia (AML) represents a significant challenge. There is little evidence that outcomes are improving for patients subjected to conventional intensive treatment. In addition, there is a large population of patients who are not considered fit for a more intensive treatment approach, and treatment options ...
Alan Kenneth Burnett, Jonathan Kell
openaire +2 more sources
Decitabine in Acute Myeloid Leukemia
Seminars in Hematology, 2005Standard induction chemotherapy, depending on patient tolerability, is at present the treatment of choice in patients with acute myeloid leukaemia (AML) under the age of 75 years. Since AML is a disease primarily of the elderly, a large proportion of patients do not receive this therapy; therefore, novel treatment modalities are warranted. In addition,
Lübbert, Michael, Minden, Mark
openaire +4 more sources
2007
The acute myeloid leukemias (AML) are a heterogeneous group of malignant diseases of hematopoietic progenitor cells with a spectrum of molecular genetic abnormalities, clinical characteristics, and variable outcomes with available treatments. A virtual explosion has been seen in the identification and characterization of disease alleles in AML in cell ...
Iris T. Chan, D. Gary Gilliland
openaire +2 more sources
The acute myeloid leukemias (AML) are a heterogeneous group of malignant diseases of hematopoietic progenitor cells with a spectrum of molecular genetic abnormalities, clinical characteristics, and variable outcomes with available treatments. A virtual explosion has been seen in the identification and characterization of disease alleles in AML in cell ...
Iris T. Chan, D. Gary Gilliland
openaire +2 more sources
New England Journal of Medicine, 1999
Löwenberg, Bob, Downing, JR, Burnett, A
openaire +3 more sources
Löwenberg, Bob, Downing, JR, Burnett, A
openaire +3 more sources
Treatment of Acute Myeloid Leukemia
2010The acute myeloid leukemias (AML) represent a heterogeneous group of malignancies derived from the pluripotent hematopoietic stem cell. These leukemias are generally characterized by genetic lesions that result in a combination of defects causing unregulated proliferation of cells and defects in cellular maturation (Gilliland and Griffin 2002).
Gibson, B +3 more
openaire +3 more sources